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DNA damageDNA damage immediate cellular response requires the activation of p53 by kinases. We found that
p53 forms a basal stable complex with VRK1, a Ser–Thr kinase that responds to UV-induced DNA
damage by speciﬁcally phosphorylating p53. This interaction takes place through the p53 DNA
binding domain, and frequent DNA-contact mutants of p53, such as R273H, R248H or R280K, do
not disrupt the complex. UV-induced DNA damage activates VRK1, and is accompanied by phosphor-
ylation of p53 at Thr-18 before it accumulates. We propose that the VRK1–p53 basal complex is an
early-warning system for immediate cellular responses to DNA damage.
Structured summary of protein interactions:
VRK1 physically interacts with p53 by anti bait coimmunoprecipitation (1, 2, 3, 4)
VRK1 physically interacts with p53 by pull down (1, 2, 3)
 2014 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Cellular reaction to DNA damage is mediated by p53 [1] that
triggers speciﬁc biological responses based on the physiological
situation of individual cells [2,3]. Mainly, the activated p53 protein
signals either to protect cells by arresting the cell cycle and to per-
mit DNA repair, or alternatively to induce cell death, thus protect-
ing the organism by elimination of damaged cells [4,5]. In order to
initiate these responses cells need to have a basal system, in which
proteins participating in damage sensing are organized in a way
that will permit their immediate reaction DNA damage detection.
This readiness state also requires that cells must always have a
basal level of p53 protein that can be immediately stabilized and
activated in response to local detection of DNA damage. Thisimmediate p53 stabilization is performed by kinases that
phosphorylate p53 in several speciﬁc residues, which play different
and sequential functional roles [6]. Initial p53 phosphorylation
determines the switch between two alternative p53 binding
modes, required for either p53 degradation by ubiquitin-ligases,
or alternatively p53-dependent transcription. This functional
switch is regulated by a unique phosphorylation in p53 in Thr-18
that is mediated by vaccinia-related kinase 1 (VRK1) [7–9]. Struc-
turally, p53-Thr18 forms a hydrogen bond with Asp21 that is nec-
essary for the correct folding of a hydrophobic a-helix and required
for the p53 direct interaction with a hydrophobic pocket in mdm2
[10]. p53-Thr18 phosphorylation disrupts this hydrogen bond
destabilizing the a-helix and resulting in loss of p53 binding to
hdm2/mdm2 [8,11–13]. Furthermore, Thr18 phosphorylation
determines a threshold of p53 transcriptional activation [11,14].
Additional p53 phosphorylation mediated by other kinases [6],
mainly in residues Ser15 or Ser20, determine the selection and
binding speciﬁcity of p53 to different transcriptional cofactors
[11,12], such as p300 or pCAF [15].
The VRK gene family appeared late in evolution and is com-
posed of three members in mammals [16,17], one member in
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ditis elegans [19], and none in yeast. This VRK gene complexity is
similar to that of the p53 gene family [20,21]. Thus, both VRK
and TP53 gene families have a parallel evolution, suggesting that
their functions might be associated, and thus represent the acqui-
sition of new levels of regulation, which are required as organisms
became more complex. The functional connection between VRK1
and p53 was already detected in germ cell proliferation in
C. elegans, in which Vrk-1 regulates cell cycle arrest triggered by
CEP-1 (p53) [22].
VRK1, the most abundant Ser–Thr kinase in nuclei [23], is a
nucleosomal/chromatin kinase that can form complexes and phos-
phorylate several transcription factors [24–26], histones [18,27–
29] and other chromatin proteins [30,31]. Moreover, VRK1 kinase
activity can also be regulated by these proteins interactions,
including those with histones [28–30]. VRK1 is also activated by
DNA damage [31]. Therefore, VRK1 is a good candidate to partici-
pate in an early response mechanism to DNA damage. This mech-
anism detects and reacts to local alterations in chromatin structure
induced by DNA damage. p53 is a transcription factor implicated in
cellular responses to stress, including DNA damage [32]. In this
context, it was proposed that p53 might be forming a complex
with VRK1 in a basal readiness state [8]. VRK1 uniquely and specif-
ically phosphorylates p53 in Thr-18 [7–9], leading to p53 stabiliza-
tion and subsequent accumulation and initiation of p53 dependent
transcription [8], which is consistent with this early role in damage
response. The resulting p53 accumulation is reversed by a novel
p53-dependent activation of autophagy that removes its activating
VRK1 [33], a p53 stabilizer, and thus permits p53 dephosphoryla-
tion and its downregulation by mdm2 [9,15,33]. Moreover, this
autoregulatory loop is altered in human cancers with p53 muta-
tions [9,34]. Human VRK1 protein has also been implicated in the
regulation of proliferation and cell cycle progression, where it
plays several roles [35]. VRK1 is required for G0 exit, behaving like
an early gene such as MYC and FOS [36]. VRK1 is also required for
phosphorylation of histone H3 and chromatin compaction late in
mitosis [27]. Moreover, VRK1 positively correlates with the prolif-
eration phenotype in human head and neck [37] and lung cancers
[34,38], and in breast cancer xenographs it also affects proliferation
[39]. In addition, VRK1 kinase activity is enhanced in response to
DNA damage and is an early participant necessary for the forma-
tion of 53BP1 foci in response to DNA double-strand breaks
induced by ionizing radiation, in both resting and dividing cells
[31]. In murine gene-trap models, VRK1 deﬁciency results in
sterility due to either meiotic defects in females or by affecting
maintenance of spermatogonial stem cells prior to meiosis in
males [40–43].
In this work we aimed to demonstrate the presence of a stable
intracellular p53–VRK1 protein complex in non-damaged cells. We
have determined that VRK1 activation in response to UV-induced
DNA damage is accompanied by an immediate phosphorylation
of p53 in Thr-18 within the complex, and that this early response
precedes p53 accumulation in cells. These results indicate that
the basal VRK1–p53 protein complex is a very early participant
in DNA damage responses (DDR).2. Materials and methods
2.1. Plasmids
Cloning of human full-length VRK1 (1–396) and VRK1DN (267–
396) into mammalian expression vector pCEFL-GST have been de-
scribed previously [44]. VRK1 mutants were generated using the
Quick-Mutagenesis system (Stratagene, San Diego, CA) and speciﬁc
primers (indicated in Table S1) following the manufacturer’sinstructions and using plasmid pCEFL-HA-VRK1 as template.
Plasmids expressing full-length human p53 and the mutants
R273H, R248H and R280K were obtained from B. Vogelstein (John
Hopkins University, Baltimore, USA) and we have used them
previously [9,33]. Plasmids expressing GST–p53N-terminal trans-
activation domains for bacterial expression were obtained from
D. Meek (University of Dundee, Scotland) and have been reported
before [7] and human GST–p53 fusion proteins 1–390, 90–290
and 290–390 were from T. Kouzaridis (Cancer Research UK,
Cambridge).
2.2. Antibodies
The p53 protein was detected with polyclonal antibody CM1
(Novocastra, Newcastle, UK) or monoclonal antibodies PAb-1801
and DO-1 (Santa Cruz, Santa Cruz, CA). Speciﬁc phosphorylation
of p53 in Thr-18 was determined with a phosphospeciﬁc
polyclonal antibody (Cell Signaling, Beverly, MA). VRK1 was
detected with either rabbit polyclonal antibodies VC or VE or with
monoclonal antibodies 1F6 or 1B5 [45]. Anti-myc polyclonal anti-
body (Upstate-Millipore, Temacula, CA) or anti-HA monoclonal
antibody (Covance, Berkeley, CA) were either used for immunopre-
cipitation of transfected proteins or as negative control in endoge-
nous immunoprecipitation assays. b-Actin was detected with the
AC15 monoclonal antibody (Sigma, St. Louis, MO).
2.3. Cell lines, transfections, immunoprecipitation and pull-down
assays
HEK293T, H1299 (p53/) and A549 cell lines were grown as
monolayers in either DMEM or RPMI supplemented with 10% foe-
tal calf serum, 2 mM glutamine, 50 U/mL penicillin and 50 lg/mL
streptomycin. Cells were detached with trypsin–EDTA solution.
All culture reagents were from Invitrogen-GIBCO. In experiments
in which plasmid constructs were transiently transfected, cells
were in exponential growth phase [9,15]. Twenty-four hours
before transfection cells were plated in P100 dishes at 60–70% con-
ﬂuence at the time of transfection as described previously [15,28].
Pull-down and immunoprecipitation experiments were performed
as reported previously [8,15]. Gels were transferred to Immobilon-
P membranes (Millipore, Billerica, MA). Proteins in membranes
were detected using a luminescence ECL kit (Amersham, GE
Healthcare). Blots were quantiﬁed in the linear response range
using an FX Personal Imager (Bio-Rad, Hercules, CA) [15].
2.4. Induction of DNA damage by UV light
DNA damage induced by UV-C light was performed with a
Stratalinker (Stratagene, San Diego, CA). Cells were starved with
media containing 0% FBS before treatment. The ultraviolet light
(UV) dose delivered was determined by direct measurement with
a radiometer Spectroline XS-254 nm-UVC (Spectronics Corpora-
tion, Westbury, N.Y.).
2.5. In vitro kinase assay
Endogenous VRK1 protein was immunoprecipitated with
monoclonal antibody 1F6 as previously reported [44,45] and the
immunoprecipitate was used for an in vitro kinase assay [46]
showing either endogenous VRK1 autophosphorylation or phos-
phorylation of GST–p53 (1–85) used as substrate [7,46–48]. The ki-
nase assay was performed at 30 C for 30 min as previously
described [47,48]. Samples were fractionated by SDS–PAGE and
radioactivity was detected by exposure to X-ray ﬁlm in the linear
response range. Quantiﬁcations were done in a Personal Molecular
Imager FX (BioRad, Hercules, CA).
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3.1. VRK1 stably interacts with p53 forming a basal protein complex
Based on observations showing that VRK1 directly phosphory-
lates p53 in Thr-18 [7]; that its knockdown results in the loss of
this phosphorylation [31,33] and that endogenous p53 and VRK1
proteins co-localize in nuclei of non-damaged [8], we asked
whether p53 and VRK1 were able to form a stable protein complex.
To detect this potential VRK1–p53 complex, reciprocal immuno-
precipitation of endogenous proteins were performed in HEK293T
cells and both proteins, VRK1 and p53, were detected (Fig. 1A),
indicating that they are indeed forming a stable basal complex in
non-damaged cells. Neither of them was detected in negative con-
trol with a non-speciﬁc antibody (Fig. 1A, bottom). The human
VRK1 protein is characterized by a well-deﬁned, but atypical,
kinase domain comprised between residues 35 and 275 with an
ATP binding site (residues 43–71) and a catalytic active site
(residues 173–185) [7,16]. Kinase domains do not form stable
complexes to permit release of its reaction products, ADP and theIP
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VRK1was required for the binding. For this aim we carried out
pull-down assays using wild-type VRK1 or kinase-dead VRK1
(K179E) (Fig. 1C). We found that the kinase-dead VRK1 interacted
more strongly with p53, which is consistent with its inability to
complete its catalytic cycle and indicates that the kinase activity
is not necessary for an stable interaction between these two pro-
teins, which is consistent with the structure of the folded protein
[49]. In Fig. 1D is shown the suggested VRK1 region involved in
the interaction with p53.
3.2. The p53 DNA binding domain (DBD) interacts with VRK1
The p53 protein has three well-deﬁned structural and func-
tional domains. The N-terminus trans-activation domain (TA) is in-
volved in selecting its interaction with either ubiquitin ligases or
with transcriptional cofactors, and its speciﬁty is determined by
the phosphorylation pattern. The DNA binding domain (DBD) is
the p53 central region, and the C-terminus has and oligomerization
(OD) and a regulatory subregions [51]. Next, we asked which of
these p53 regions was implicated in its binding to VRK1. We per-
formed pull-down assays using p53 fusion constructs expressing
the different domains of p53 and endogenous VRK1 (Fig. 2A) and
we found that VRK1 was able to bind only to full-length p53 (res-
idues 1–390) and to its DNA binding domain (residues 90–290).C
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3.3. p53 DNA contact mutations do not disrupt its interaction with
VRK1
The TP53 gene is frequently mutated in many types of cancer,
and most of these mutations occurred within the DBD [52].
Because we identiﬁed that VRK1 binds to p53 through this region
we analysed whether some of these common p53 mutations [53]
affected its binding to VRK1. For this aim we performed pull-down
assays using transfected HEK293T cells with GST-VRK1 and differ-
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immunoprecipitation of endogenous VRK1 in H1299 cells transfec-
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that all mutant proteins stably interacted with VRK1; however,
the interaction with the conformational mutant R175H wasding
n
292
OD
319-359 390
BD
290
290 390
B 293T
VRK1 
GST-p53
Pulldown
Lysate
VRK1 
GST 
G
ST
-p
53
 1
-8
5
G
ST
-p
53
 1
-6
4
G
ST
-p
53
 1
-6
3
G
ST
Ponceau
β- actin
A binding domain of p53. HEK293T cell lysate was used in pull-down assays with
nt regions of p53. (B) VRK1 does not bind with the trans-activation domain of p53.
cts expressing different regions of p53N-terminal protein. VRK1 was detected with
g the location of VRK1 interaction with p53. TA: transactivation domain; DBD: DNA
BA p53
R
17
5H
p53
GST-VRK1
GST
β-actin
p53
GST-VRK1
GST
+  – +  – +   –
– +  – +  – +
wt R
28
0K
Pull-down
R
24
8W
wt wt R
27
3H
GST-VRK1
GST
Lysate
+  – +  –
– +  – +
+  – +  – +   –
– +  – +  – +
p53
VRK1
IP: α-VRK1 
Lysate
Em
pt
y 
ve
ct
or
p53
VRK1
p53
R
17
5H
R
24
8W
wt
Em
pt
y 
ve
ct
or
p53
R
17
5H
R
24
8W
wt
β-actin
0
0,5
1
1,5
2
2,5
3
3,5
4
4,5
wt R175H R248W R273H R280K
p5
3/
VR
K1
 re
la
tiv
e 
va
lu
e
p5
3/
VR
K1
 re
la
tiv
e 
va
lu
e
0
0,5
1
1,5
2
2,5
3
3,5
4
4,5
wt R175H R248W
Fig. 3. Interaction of p53 mutants with VRK1. (A) HEK293T cells were transfected with pCEFL-GST-VRK1 plasmid or control GST and p53 mutants cloned in a pCMV vector.
Cell lysates were used for a GST pull-down and the presence of p53 was detected in western blots. The ratio of p53 bound to the retrieved VRK1 was quantiﬁed in the linear
response range and is represented in the graph (bottom). (B) Interaction of endogenous VRK1 from H1299 cells with transfected wild-type p53 and R175H and R248W
mutants. VRK1 was immunoprecipitated with a mixture of polyclonal antibodies (VC and VE) and the bound p53 was detected in immunoblot (top). The blot was quantiﬁed
and the relative amount of p53 bound to VRK1 is represented in the graph (bottom).
696 I. López-Sánchez et al. / FEBS Letters 588 (2014) 692–700approximately four times stronger compared to control wild-type
or the contact-DNA mutant R248W. These ﬁndings also indicate
that the interaction of VRK1 with p53 in the DBD occurs by the
globular region that is not directly interacting with DNA grooves.
3.4. The basal VRK1–p53 complex is immediately activated in response
to UV light treatment
VRK1 kinase activity is regulated by the folding of its C-terminal
region [29,49] that results in a conformational change in native
protein that is recognized by a speciﬁc monoclonal antibody
(1B5) [45]. Previous work has shown this structural change in cells
upon DNA damage response to ionizing radiation [31]. Because we
have detected a stable VRK1–p53 complex in non-damage cells
next we asked whether this complex could be activated in re-
sponse to DNA damage and consequently have an effect on bothproteins. Therefore, we determined if this conformational change
was detected in nuclear VRK1 after induction of DNA damage by
UV-light (Fig. S3A). We found that in UV-treated cells there was
a 30% increase in VRK1 nuclear staining detected with the 1B5
monoclonal antibody by immunoﬂuorescence. This increase in
reactivity reached its maximum value at short times, ﬁve to ten
minutes, after UV-irradiation. No variation in VRK1 nuclear protein
reactivity was observed using a polyclonal antibody that does not
detect the conformational change (Fig. S3A). VRK1 protein levels
are not affected by UV-light treatment as shown by immunoblot-
ting analysis using the 1B5 antibody to detect the denatured
VRK1 protein (Fig. S3B). Based on this initial observation we
proceeded to examine if the kinase activity of VRK1 was enhanced
upon UV-light treatment. For this aim we carried out an in vitro
kinase assay with endogenous VRK1 protein immunoprecipitated
from HEK293T cells treated or not with UV-light and GST–p53
I. López-Sánchez et al. / FEBS Letters 588 (2014) 692–700 697(residues 1–85) used as substrate (Fig. 4A). We found that UV-light
treatment increased between 6 and 12-fold the level of both VRK1
autophosphorylation (activation) and p53 phosphorylation (Fig 4A,
graph). This observation led us to investigate if VRK1 activation
could also result in an increase in p53 phosphorylation at Thr-18
after UV-induced DNA damage. For this assay, we focused on the
endogenous p53 protein that is forming part of the basal VRK1–
p53 complex. For this aim HEK293T cells were treated with UV
light and a time course was performed to measure the speciﬁc
phosphorylation of p53 in Thr-18 present in the immunoprecipi-
tated complex (Fig. 4B). We found that the VRK1–p53 complex is
already detected in non-treated cells. At short times after UV treat-
ment, the protein levels of both VRK1 and p53 remained constant,
but there is an increase in p53-Thr18 phosphorylation in the p53
immunoprecipitated complex that also contain VRK1 (Fig. 4B). This
immediate accumulation of phosphorylated p53 in Thr-18 was
quantiﬁed (Fig. 4B, graph). These results are consistent with thep5
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assay. The ratio of phosphorylated to total protein was quantiﬁed in the linear response ra
Thr18 phosphorylation complexed with VRK1. Serum deprived HEK293T cells were irradi
points. The level of Thr18-phoshorylation was determined with a phosphospeciﬁc ant
determined. The amount of p53, p53-Thr18-P and VRK1 proteins was quantiﬁed in the lin
was immunoprecipitated either with a negative control antibody as well as with anti-p53
cells. In non-damaged cells, VRK1 and p53 form a stable complex ready to respond to inju
activates p53 by phosphorylation at Thr-18, which precedes its accumulation (right).loss of p53-Thr18 phosphorylation detected in UV-treated [33],
or treated with ionizing radiation [31], in which VRK1 was knocked
down. These ﬁndings indicate that there is an early p53 switch to-
wards its transcriptional activation mode as a consequence of its
immediate phosphorylation by VRK1 in Thr-18 that is inducible
by DNA damage and precedes p53 accumulation. Thus we con-
clude that speciﬁc phosphorylation of p53 at Thr-18 is an immedi-
ate event occurring in the pre-existing basal p53–VRK1 complex
during the cellular response to UV-induced DNA damage. In
Fig. 4C is shown the proposed model of the VRK1–p53 complex
dynamics upon UV-induced DNA damage.
3.5. VRK1 is integrated in DNA-damage response pathways
The direct interaction and phosphorylation of p53 by VRK1 and
other proteins implicated in DNA damage responses led us to start
the elucidation of the early steps in the signalling pathway0
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698 I. López-Sánchez et al. / FEBS Letters 588 (2014) 692–700responding to DNA damage. In this context, VRK1 is highly likely to
play a coordinating role among the different DDR signalling com-
ponents and sequential processes, which range from damage
detection to assembly of speciﬁc repair systems and ﬁnally resto-
ration to normal chromatin structure. Thus, the proteins interact-
ing with VRK1 were analysed using the Intact database with the
Cytoscape software [54] that outlined the initial components of
the VRK1 pathway in the context of proteins associated to DNA
damage responses and transcription factors (Fig. 5). The formation
of a complex between accumulated p53 mutants and VRK1 can re-
sult in sequestration of VRK1 and have an effect on VRK1 depen-
dent functions.
4. Discussion
Any DNA structural alteration must be detected as a locally al-
tered chromatin, which should activate chromatin kinases and ini-
tiate a complex process aiming to achieve the full reparation of
damaged DNA. This process requires several sequential steps
implicating different components [55,56]. Mechanistically, local
distortion of chromatin as a consequence of DNA damage should
alter proteins directly interacting with histones. In this context
VRK1, which is a nucleosomal histone kinase whose activity is reg-
ulated by histone interactions [27,29], is a very likely participant in
sensing and initiating the early response to DNA damage by regu-
lation of transcription factors implicated in DDR, such as p53[8,33]
or c-Jun [25], since both are targeted by VRK1. The basal interac-
tion between wild-type p53 and VRK1 forming a stable complex
in non-damaged cell suggests a well-deﬁned sensing role for this
protein complex in DNA-damage responses. The main role of the
VRK1–p53 complex is a fast initial response by sensing the locally
altered chromatin structure that activates VRK1 to phosphorylate
p53 in Thr18 [7], which switches p53 to a transcription factor bind-
ing mode [11,13], triggering p53-dependent DDR. The detection of
this VRK1–p53 protein basal complex is also consistent with one of
the roles of VRK1 within the nucleus, the formation of VRK1 com-
plexes by direct interactions with transcription factors that areFig. 5. Connectivity map between VRK1 and proteins implicated in DNA-damage respon
IMEx databases (EBI-EMBL) for binary interactions that were not spoke expanded (PMID:
of the VRK1 pathway in the context of proteins associated to DNA damage responses an
Transcription factors. Light yellow: cell cycle proteins. Blue: Chromatin modifying enzygradually regulated by p53 activation [13,14]. Thus, formation of
a protein complex between VRK1 and p53 adds another transcrip-
tion factor to those that are already known to stably interact with
VRK1, which can have functionally different consequences based
either on the interaction with p53, wild-type or mutated, and on
protein levels in individual cell types. The pre-existing complex
formed by VRK1–p53 suggests a very early role for VRK1 in DNA
damage-responses (DDR), and is also consistent with previous
observations in which VRK1 knockdown prevented the activating
phosphorylation of ATM, CHK2 and DNA-PK, as well as p53-
Thr18 phosphorylation, in response to ionizing radiation [31].
The formation of a VRK1–p53 complex can have additional ef-
fects based on the roles that are performed by each individual par-
ticipating protein. p53 mutations in the DNA binding domain are
unable to induce their own downregulation mediated by gene
expression of HDM2/MDM2 coding for an ubiquitin ligase and
resulting in p53 mutant accumulation. Moreover, this defective
induction of gene expression by p53 also affects downregulation
of VRK1 protein [33]. VRK1 downregulation is mediated by p53
transcriptional activation of DRAM (damage-regulated autophagic
modulator) [57]. DRAM targets VRK1 to enter in the autophagic
pathway [33] and thus be degraded in the lysosome [9,15]. This
autoregulatory loop is altered in tumours with p53 mutations
[34], resulting in an accumulation of VRK1 protein, which has been
detected in human lung [34] and head and neck squamous cell car-
cinomas [37].
The situation in tumours harbouring p53 mutations is very
likely to be functionally different [58]. Mutant p53 proteins accu-
mulate in cells and can be targeted by kinases, and be also able
to interact with and sequester other cellular proteins. Thus, p53
mutant direct interaction with other cellular proteins is very likely
to alter their normal function. The differential interaction among
p53mutants and VRK1 can contribute to partly explain their differ-
ential effects. Differences in biological effects have already been
associated to different p53 mutations [53,59,60], which may also
be dependent on cell type and its interactome. The p53 mutants
R175H and R273H appear to facilitate cell invasion by interactionses (DDR) and repair. The proteins interacting with VRK1 were analysed using the
22453911) with the Cytoscape software [54], which outlined the initial components
d transcription factors. Red: proteins implicated in DNA-damage responses. Purple:
mes. Pink: other proteins.
I. López-Sánchez et al. / FEBS Letters 588 (2014) 692–700 699with the NRD1 metalloprotease [61], or by modulating MET signal-
ling [62]. Also p53 mutants, by their incorporation in gene promot-
ers containing the SREBP transcription factor can regulate genes in
the mevalonate pathway [63]. Furthermore, p53 mutant proteins
can also bind to other cellular proteins and interfere with their
function, such as the Mre11 complex [64]. High levels of mutant
p53 proteins can also interact with transcription factors [65] or
transcriptional co-activators. Therefore, p53 mutants can be inte-
grated in different gene promoters and might alter their normal
functions [59,66].
In addition the accumulation of p53 mutants can also sequester
VRK1, and consequently the formation of a protein complex be-
tween mutated p53 and VRK1 might result in the formation of pro-
tein complex that might interfere with other VRK1 dependent
functions, such as VRK1 responses to DNA damage [31,33]. In addi-
tion, mutated p53 can sequester VRK1 from its participation in
other transcriptional complexes, such as those between VRK1
and Jun [25], ATF2 [26] or CREB [24] and therefore might affect
the expression of genes regulated by these transcription factors.
In this work we have shown that VRK1–p53 are forming part of
a basal endogenous protein complex in non-damaged cells, which
is immediately activated by induction of DNA damage with UV
light, accompanied by a speciﬁc phosphorylation of p53 and acting
as an early response system.
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